Genetic-guided treatment planning for high-risk early breast cancer
Part of Cancer, Skin clinical trials.
This study uses tumor genetic testing to help plan more precise treatment for people with early high-risk breast cancer. You may be asked to give a recent tumor sample so researchers can match your cancer features with the best available options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have breast cancer
- Your cancer is early-stage and planned for curative treatment (or a limited, local relapse that can be cured)
- Your enrollment timing fits one of these situations: before neoadjuvant chemo, after neoadjuvant chemo but before surgery (not fully responding), or after surgery with certain non-complete response features
- You are willing and able to donate a recent tumor tissue sample for genetic testing (fresh tissue is preferred)
- You can sign (and keep) the study consent form and follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment approach for people with metastatic (advanced spread) breast cancer using tumor testing. It may help guide doctors toward better-matched therapies based on genomic (DNA) information from your tumor.
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.